Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ProMIS NeurosciencesPMN -1.61%35 Equity-to-Asset is 0.87 as of Jun. 2026, which is 200% above its 10-year median of 0.29. GuruFocus rates PMN with a GF Score™ of 35/100. The stock has 1 warning sign investors should review. Among 1,414 Biotechnology companies, ProMIS Neurosciences ranks better than 77.16% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
ProMIS Neurosciences Equity-to-Asset Related Terms
ProMIS Neurosciences Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for ProMIS Neurosciences's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PMN vs GNLX, NTHI, VXRT: Equity-to-Asset Comparison
For the Biotechnology subindustry, ProMIS Neurosciences's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ProMIS Neurosciences Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ProMIS Neurosciences's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where ProMIS Neurosciences's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
ProMIS Neurosciences's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ProMIS Neurosciences (PMN) has a Equity-to-Asset of 0.87 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on ProMIS Neurosciences and its competitors. This is 200% above median its historical median of 0.29. According to the industry distribution chart, ProMIS Neurosciences ranks #323 out of 1414 companies in the Biotechnology industry, placing it in the top 22.8%.
Is ProMIS Neurosciences' Equity-to-Asset too high?
ProMIS Neurosciences' current Equity-to-Asset of 0.87 is 200% above median its 10-year median of 0.29. The Biotechnology industry median Equity-to-Asset is 0.69. ProMIS Neurosciences' value of 0.87 is 26.1% above this industry median. Based on the distribution chart, ProMIS Neurosciences ranks #323 out of 1414 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, ProMIS Neurosciences has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does ProMIS Neurosciences' Equity-to-Asset compare to GNLX and NTHI?
According to the Biotechnology industry distribution chart, ProMIS Neurosciences ranks #323 out of 1414 companies for Equity-to-Asset. This places ProMIS Neurosciences in the top 23% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.69. ProMIS Neurosciences' value of 0.87 is 26.1% above this benchmark. While the company's 10-year median is 0.29 vs. the industry median of 0.69, ProMIS Neurosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.69, based on 1,414 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ProMIS Neurosciences's current Equity-to-Asset of 0.87 is 26.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on ProMIS Neurosciences and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ProMIS Neurosciences's current Equity-to-Asset is 0.87, which is 200% above median its own 10-year median of 0.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProMIS Neurosciences stock overvalued right now?
ProMIS Neurosciences (PMN) has a current Equity-to-Asset of 0.87. The current Equity-to-Asset is 0.87, which is 200% above median its 10-year median of 0.29 and 26.1% above the Biotechnology industry median of 0.69. ProMIS Neurosciences' overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For ProMIS Neurosciences (PMN), the current Equity-to-Asset is 0.87 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.
35GF Score
Get the complete analysis for PMN
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PMN has been successfully added to your 
